BiomimX

BiomimX has developed a suite of advanced “Beating Organs on Chip” platforms that provide dynamic mechanical stimulation to human-derived microtissues. Their flagship product line includes the first Gut-on-Chip model capable of replicating both intestinal architecture/functionality and peristaltic-like movements with integrated microbiome analysis. The technology has demonstrated the ability to distinguish between responders/nonresponders in melanoma immunotherapy by identifying specific biomarkers and microbial factors linked to clinical outcomes. These innovations are accelerating drug discovery/development by providing more predictive preclinical data while reducing reliance on animal models.